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1. Introduction
Central nervous system (CNS) repair and regeneration following traumatic injury or disease
pathology is a widely studied and widely debated field. This book chapter will outline the
pathology of spinal cord injury (SCI) with particular focus on how it lends itself to cell-based
intervention. Next, we will outline the different populations of cells proposed for SCI treat‐
ment, including neural stem/progenitor cells (NSPC), and methods of generating clinically
relevant NSPCs from adult tissue, embryonic stem (ES) cells and induce pluripotent stem (iPS)
sources. Lastly, we will examine the use of NSPCs in SCI models with a specific focus on how
the environment affects the transplanted population and how the transplanted cells modulate
the spinal cord niche.
2. Pathology of spinal cord injury
Spinal cord injury (SCI) is a devastating event that significantly affects the morbidity and
quality of life in adults (Average age of patients at the time of injury is 38.0 years old). [1] The
prevalence of traumatic SCI worldwide is approximately 750 per million with an increasing
annual incidence. [2] In order to be able to develop effective treatments for SCI, it is necessary
to have a detailed understanding of the pathophysiological events that happen during SCI in
the body and how they interact with each other to cause the functional deficits seen in patients.
These events have complicated roles post-SCI. For example, the inflammatory response and
reactive astrogliosis that are seen post-SCI have damaging and neuroprotective and –restora‐
tive effects. [3]
© 2013 Salewski et al.; licensee InTech. This is an open access article distributed under the terms of the
Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits
unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
The pathophysiology of SCI is biphasic; it consists of a “primary” and a “secondary” stage.
The primary injury is the result of an initial mechanical insult, which is followed by a series of
cellular and molecular events that, in turn, lead to further destruction of the spinal cord tissue.
It is well known that the mechanical injury seldom results in complete transection of the spinal
cord. Most fracture dislocations or burst fractures of the spine result in disc displacement into
and laceration or compression of the cord resulting in blood vessel, axonal and cellular
membrane disruption.
Decreased blood supply to the tissue and cells of the spinal cord results in nutrient and oxygen
deficiency in the injured tissue, which in turn is followed by a cascade of biochemical or
“secondary” events that eventually lead to further tissue necrosis. [3-5] Thus, the primary
insult precedes sequential pathological changes such as further vascular dysfunction and
hemorrhage, edema, ischemia, excitotoxicity, electrolyte shifts, free radical production,
inflammation, axonal and neuronal necrosis, demyelination, cyst formation and infarction. [5]
The events will be discussed in further detail in following sections and are summarized in
Figure 1.
Figure 1. Mechanisms of Injury in SCI. SCI pathology results from several mechanisms occurring both concurrently and
in sequence. Primary mechanical insult results in initial loss of axons (1) and demyelination (2). Subsequent secondary
injury is characterized by further neuronal/axonal cell death (1) and myelin degradation (2), usually due to secondary
inflammation from infiltrating lymphocytes and monocytes (3) and also reactive oxygen species secreted by activated
astrocytes composing the glial scar (4). Both the glial scar (4) and post-traumatic cyst or syrinx formation (5) pro- vide
physical impediments to regeneration, and cyst formation can further damage neurons by exerting physical pressure
on their damaged axons. * from Ruff and Fehlings. (2010). Panminerva Med 52:125-147, with permission
SCI is a complex set of damaging events that occur at the cellular level and it can be divided
into four main stages: the immediate, acute, intermediate, and chronic phase of SCI.[3] The
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first two hours post-SCI is the immediate stage during which the body is going through
processes as a result of the primary injury itself. Severing of axons, neural and glial death, and
spinal shock, all instantly result in loss of function below and at the level of the injury. The
spinal cord becomes swollen which is accompanied by hemorrhage into the grey matter,
cellular necrosis, vascular disruption and ischemia. Vascular disruption leads to further
hemorrhage into the white matter and, as a result of the combined effect of edema and
hemorrhage, many segments of the spinal cord, rostral and caudal to the site of injury, become
ischemic. [6] Even though gross histopathological changes may not be visible at this stage,
many pathophysiological events have already started. For example, activation of microglial
cells and an instantaneous increase in pro-inflammatory cytokines TNFand IL and excitotoxic
levels of extracellular glutamate can be detected within minutes of an injury. [3, 7, 8]
2.1. Stages SCI progression
2.1.1. Acute stage
During the acute stage of the SCI, the events of the secondary injury prevail. This is subdivided
into early acute (2-48 hours) and subacute (2 days-2weeks). Vascular disruption, hemorrhage,
and the resulting ischemia are central constituents of the early acute stage [5, 7], which result
in the loss of normal autoregulatory mechanisms. The loss of ionic homeostasis immediately
following SCI and excitotoxicity are closely related processes that each significantly contribute
to the propagation of cellular injury after SCI. The ionic deregulation plays an important role
in increasing necrosis and cell death following SCI. For instance, irregularity of Ca2+ concen‐
tration initiates activation of calpains and caspase cascades which in turn cause further cellular
apoptosis. [9] Additionally, activated microglia express FAS ligand receptors and signaling
through the p75 neurotrophin receptors that initiate the caspase and calpain cascade leading
to proteolysis and DNA cleavage by effector caspases and trigger even further apoptotic cell
death. [10] As a result of these events, a large number of cells, including oligodendrocytes, die.
In addition to death of the neural cells, loss of calcium, sodium and potassium ionic channel
homeostasis, and demyelination disrupt signal transduction in the spinal cord and result in
sensorimotor inactivity and paralysis. [3-5]
The extracellular levels of glutamate rise rapidly due to direct injury to cells and failure of
energy-dependent transporters, notably the Na+K+ adenosine triphosphatase membrane
transporter that normally functions to regulate extracellular concentrations of ions, glutamate,
and other molecules. [11] Excessive activation of glutamate receptors leads to an increase in
the influx of Na+ and Ca2+ through the NMDA and alpha-amino-3-hydroxy-5-methyl-
isoxazoleproprionate/kainate receptors and excitotoxicity. [12] This causes further neural and
glial death.
Reactive oxygen (O2) species (ROS) is at detectable levels 12 hours after SCI and remains
elevated for almost one week, returning to preinjury levels 4-5 weeks post-injury. The
increased amount of ROS leads to increased membrane lipid oxidation and an increase in
cellular lysis, organelle damage and Ca2+ ion concentration irregularities. [13, 14] It has been
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shown that Peroxynitrite, which is generated through reaction of ROS and nitric acid, is directly
involved in the induction of neural apoptosis in rat SCI. [13]
The brain blood barrier (BBB) is a highly selective endothelial filter for transport of compounds
in and out of the central nervous system. This becomes highly permeable as a result of the
primary mechanical insult to the cord and presence of inflammatory mediators. It has been
shown that peak BBB permeability occurs at 24 hours following injury in the rat and returns
control levels by 2 weeks. [15] Two inflammatory mediators – TNF and IL-1 - are known to
increase vascular permeability. In addition, other compounds released by glial cells or
invading immune cells which are believed to play a role in increasing BBB permeability include
ROS, nitric oxide, histamine, matrix metalloproteinases, and elastase. [3, 13] Additionally,
disruption of the vasculature following SCI results in the breakage of the BBB, leading to an
inflammatory response and infiltration of astrocytes, microglia, T cells, neutrophils, and
invading monocytes. Invasion of macrophages and neutrophils to the site of injury increases
cellular disruption and causes further inflammatory-triggered necrosis. Inflammation then
results in activation of microglia which, together with leukocytes, cause malfunction of
oxidative metabolism in demyelinated axons and proliferation of astrocytes as well as
increased expression of glial fibrillary acid protein (GFAP) and the formation of a glial or
astrocytic scar. [2-4] Further to this, a multitude of noncellular mediators, including TNF,
interferons, and ILs play important roles.
The inflammatory response in SCI is a highly complex event with a dual nature. Some aspects
of the inflammatory response further advance the secondary injury phase, while others are
beneficial in removing cellular debris and starting the regenerative process [16]. For instance,
TNF plays an important role in cellular death post-SCI and its inhibition has been shown to
result in functional neurological recovery after SCI. However, it has also been shown to have
a neuroprotective role in in vitro and murine models of SCI. [17, 18]
2.1.2. Subacute phase
The subacute phase lasts from 2 days to 2 weeks after the initial injury. This is the stage where
it is hoped that therapeutic strategies currently in development, including cellular treatments
and strategies, will be helpful. For instance, we have shown in our lab that transplantation of
adult murine neural precursor cells at 2 weeks post-injury promotes remyelination and
functional recovery. Such effects were not seen when the cells were transplanted at later time
points or during the chronic stage of the injury. [19] Keirstead et al, have also reported the
failure of transplanted human ESC-derived oligodendrocyte progenitor cells to survive,
migrate and promote functional recovery when they were injected to the site of injury either
at the time of injury or after the subacute phase. [20]
During the initial hours to days following SCI, astrocytes undergo cytotoxic edema and
necrotic cellular death; however, a second delayed astrocytic response happens during the
subacute phase. During this stage, there is a significant increase in the astrocytic intermediate
filament GFAP as a result of the proliferative and hypertrophic activity of astrocytes. These
reactive astrocytes form the astrocytic (gliotic) scar through their interweaving cytoplasmic
processes, which becomes a physical and chemical barrier to axonal regeneration. It is
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important to note that in humans, there is significantly less astroglial scarring observed than
is observed in rodent SCI models. [21] Other than scar formation, astrocytes also promote the
reestablishment of ionic homeostasis and the integrity of the BBB, which is beneficial in
decreasing edema and immune cell infiltration. [22]
During the subacute stage of the injury, there is a significantly higher phagocytic response
observed in the CNS compared to the PNS. While this could partly account for the lack of
regenerative ability seen in the CNS, the phagocytic response is believed to be efficient in cell
debris removal and, to some extent, in promotion of axonal growth inside the lesion. [13]
2.1.3. Intermediate phase
The intermediate phase starts at two weeks and continues to 6 months post-injury. Main
characteristics of this stage are continuous maturation of the gliotic scar and the start of axonal
regeneration. Regenerative axonal sprouting has been observed in corticospinal tract axons in
rat models of contusive SCI from 3 weeks to 3 months following injury, and reticulospinal
fibers have been observed from 3 to 8 months post injury. [23] It is encouraging to observe that
regenerative potential still exists in adult spinal cord, however, these regenerations have not
been able to produce significant functional recovery in severe SCI.
2.1.4. Chronic phase
The chronic phase starts about 6 months after the initial SCI and lasts throughout the lifetime
of the SCI patient. Further gliotic scar formation, development of cysts and syrinxes within the
lesion, and continuous Wallerian degeneration of severed and injured axons are the main
characteristics of this stage. [3, 23-25] Two to three years post-injury, the lesion has usually
stabilized and is characterized by formation of a cyst cavity and mayelomalacia, which is the
final stage of necrotic death. [26] Treatment strategies at this stage focus on rehabilitative
approaches to promote plasticity, regeneration and remyelination of injured axons. Unfortu‐
nately, to date there has not been any report of the application of stem cells at this stage
resulting in any significant functional improvement.
2.2. Cell-based approaches in SCI
As explained in the previous section, in the pathophysiology of SCI, some processes can be
considered to be double-edged swords with both positive and negative effects and interations.,
These are not yet completely understood. One example of such an interaction is the astrocytic
response which, on one hand results in the development of astrocytic scar limiting axonal
regeneration and functional recovery, and on the other results in reestablishment of the BBB,
ionic homeostasis, and decreased immune cell infiltration. What makes the pathophysiology
of SCI and the translation of treatment strategies into the clinic even more complicated is its
variance and uniqueness among different patients with different cases of injury. Experimental
SCI models, which are mostly rodent models, consist of a homogeneous population, in contrast
to the vastly heterogeneous human SCI population.
Regenerative Medicine
http://dx.doi.org/10.5772/55054
275
Two main aims of cell-based treatment for SCI are replacing lost or injured cells such as
oligodendrocytes and neurons, or providing the cells with a microenvironment that supports
or enhances the neuroprotective and regenerative ability of cells within the lesion. Stem and
progenitor cells, and Schwann cells are examples of cells that are being used in studies to
replace lost cells. Additionally, many studies have shown that these cells have the ability to
remyelinate axons in the injury site while also providing them with supportive growth and
neuroprotective factors. [1, 19, 27-29]
3. Cell populations for SCI treatment
Even though modern surgical and medical treatment approaches have dramatically decreased
mortality rate due to SCI, current clinical techniques provide only modest efficacy in improv‐
ing outcomes for patients, especially during the chronic stages of the disease. Thus, there is a
need for new techniques that could improve recovery for SCI patients. Cell replacement
strategies use stem cells because of their long-term proliferative abilities and the trophic
support they provide to the regenerating tissue. In the following sections we will briefly review
different types of stem cells that are being investigated as cell sources in therapeutic ap‐
proaches for SCI.
3.1 Cell types used in SCI therapy
3.1.1. Mesenchymal stem cells
Multipotent mesenchymal stem cells (MSCs) are non-hematopoietic multipotential progenitor
cells that were initially characterized by Caplan as cells with self-renewing capacity that can
give rise to skeleton and other lineages of the mesenchyme through the mesengenic process
[30, 31]. However, with the exception of a few stem cells, which are progenitors with “clonal
self-renewal and multilineage potential”, MSCs represent a non-homogenous population of
cells and not all of the cells have the same potential for differentiation. Therefore, the Interna‐
tional Society for Cellular Therapy (ISCT), suggests usage of the term, “Multipotent mesen‐
chymal stromal cells”, for the plastic adherent population of cells isolated from stromal tissue
of bone. [32] Additionally, in 2006 Dominici et al., from the International Society for Cellular
Therapy, defined a minimum set of criteria for MSCs some of which include lacking hemato‐
poietic cell surface markers such as CD34 (endothelial marker) and CD45 (pan-leukocyte
marker), and containing cell surface markers such as CD105 (endoglin), CD90 (Thy-1), and
CD73 (ecto 5’ nucleotidase) and to be able to generate at least three lineages of the mesenchyme
[33]. MSCs are primarily isolated from bone in adults but they also reside in adipose tissue,
cartilage, synovium, periosteum, muscles and fetal tissue such as placenta and umbilical cord.
There are many studies on the application of MSCs to SCI models with variable reports on the
ability of the cells to survive, integrate, and differentiate into neuronal lineages. [34] MSCs
from both rats and humans have been shown to be capable of generating neural morphology
and expressing neural and astrocytic markers in vitro. However, they have similar differen‐
tiation profiles only when transplanted into an embryonic or developing CNS. When trans‐
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planted into adult rat CNS, neither rat nor human MSCs were able to differentiate into neuronal
cells. Mostly, they generated perivascular macrophages in the rat brain. [35-37]
There are other studies in which transplanted MSCs were tracked in rat or mouse injury models
through GFP or electromagnetic tagging coupled with immunochemistry and MR imaging.
Even though both types of studies report functional improvements, only a fraction of cells are
reported to show expression of neuronal or astrocytic markers and only a very small number
of cells are reported as having differentiated into neurons. [37-39] There are differing reports
on the extent of MSC transplantation benefits in functional recovery. MSCs have shown to be
effective at 4 weeks up to 1 year after the injury [41], depending on the timing of transplantation
from the time of injury [40] to 1 week [37, 38, 41], or 3 months post injury [42]. Other studies
show lack of any functional benefit observable through the Basso Beattie Bresnahan (BBB) open
field locomotor scoring system. [43] However, all of the mentioned studies report on the ability
of MSC transplants to preserve the injured tissue, both gray and white matter, and to provide
micro environmental cues supportive of axonal growth, rather than replacing lost cells. [42,
43] Given the inconsistency seen in the results of transplanting MSCs into SCI models in rats,
mice and primates, it is necessary to have a better understanding of the type of cells in the MSC
population that are being transplanted[44] and investigate all the possible mechanisms behind
the functional recovery observed in these models.
3.1.2. Schwann cells
Schwann cells are the myelinating cells in the peripheral nervous system. Since the first
transplantation of SCs into SCI by Duncan et al. in 1981 [34], these cells have been used in many
different SCI models and have been shown to be able to remyelinate axons and provide a
permissive environment for them to regenerate and grow. Binge et al. [45] showed that SCs
also have a small but significant effect on increasing functional recovery. However, their
remyelinating and regenerating ability does not go beyond the growth-permissive surface,
which explains why there is only a slight improvement in functional recovery. [3, 44-46]
Additionally, it has been shown that axons in the corticospinal tract (CST) remain unaffected
by SC transplants. [34] Also, they have been shown to generate a more active astrocytic
response compared to other cell types such as NPCs which results in less efficient integration
of these cells into the injured spinal cord. [34] As a result, the clinical application of SCs alone
for SCI treatment appears extremely limited.
To overcome this limitation, many combinatorial strategies have evolved which associate SCs
with growth factors or bioengineering scaffolds and other cells types to enhance recovery. [4,
47-50] Additionally, new sources for SCs are being investigated such as skin derived precursor
cells from the dermis of the skin [51-54] and MSCs. [55-58] However, it is yet to be proven
whether these cells hold any advantage in treating SCI compared with SCs that are derived
from the PNS.
3.1.3. Olfactory ensheathing cells
OECs are glial cells derived from the olfactory bulb or lamina propria of the olfactory mucosa
and are termed olfactory nerve Schwann cells due to morphological similarities to SCs. Having
a lifelong capacity to proliferate and being able to facilitate passage of new axons from
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regenerating receptor neurons in the PNS in the olfactory mucosa to the target neurons in the
CNS in the olfactory bulb glomeruli, has made them an excellent candidate for cell treatment
strategies in SCI. [58, 59] They may be specifically advantageous when co-transplanted with
SCs, since they can overcome SCs’ limitations in passing the transplant graft and entering the
injured CNS environment to produce functional synapses. [3, 60, 61]
OECs create a permissive environment for axonal growth and regeneration by interacting with
the astrocytes in the glial scar and promoting angiogenesis. [62] This neuroprotective effect
has led to their use in numerous clinical trials outside North America. However, they all report
mixed results with none showing a significant benefit. [3, 27] Additionally, there are numerous
axonal regeneration claims seen in OEC literature, which have not been confirmed by other
studies and there are inconsistent reports on their regenerative capacity in vivo. The reasons
for such discrepancies are not completely understood but could be attributed to variability in
cell sources, cultures, and injury models studied. [63, 64] Thus, there is a need for further
studies on the biology of OECs and more refined criteria set for isolation of these cells in order
for their translation into the clinic to be feasible. [34]
3.1.4. Neural stem/progenitor cells
Neural Stem/Progenitor Cells (NSPCs) are multipotent stem cells that self-renew and differ‐
entiate into lineage-specific neural precursor cells, which can give rise to neurons, astrocytes,
and oligodendrocytes through asymmetric cell division. [30] Indeed, neural precursor cells
and oligodendroglial precursor cells have been shown to replace damaged cells, secrete trophic
factors, regulate gliosis and scar formation, reduce cystic cavity size and axonal destruction,
as well as to remyelinate axons.[3, 27, 65] However, the scarcity of adult NSPCs limits the
clinical translation of transplanting these cells in injured tissue. Therefore, alternative routes
to derive NSPCs have been studied.
4. Generation of NSPC from various sources
4.1. Adult tissue derived NSPCs
NSPCs can be derived from various regions along the neuroaxis during embryonic develop‐
ment and in adult life [66, 67]. These cells retain their mulipotentiality and can generate neural
cells in culture. NPSCs have been isolated from the subependymal zone of the adult mammali‐
an brain and from ependymal and non-ependymal regions of the adult mammalian spinal cord.
[68-70] Single adult NPSCs can be isolated in vitro in the presence of growth factors (epithelial
growth factor, EGF; fibroblast growth factor, FGF) that enable the proliferation and formation
of clonally-derived free-floating colonies. The differentiation and survival of cellular subpopu‐
lations can be promoted in vitro by exposure to bone morphogenetic proteins (BMPs) to produce
astrocytes [71, 72], insulin-like growth factor (IGF)-I, interleukin-1 (IL-1), Neuregulin-1 (Nrg-1)
to generate oligodendrocyte [73, 74], and neurogenin-2 to produce neurons [75, 76].
For experimental purposes neurospheres can be generated from the germinal zone of the adult
mouse brain, according to well-established techniques [77, 78]. Briefly, the subventricular zone
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(SVZ) of the forebrain of mice can be dissected and transferred to a low calcium aCSF solution.
Cells are plated on uncoated tissue culture flasks in serum free medium containing FGF2 and
EGF for 7 days. The neurospheres are passaged weekly by mechanical dissociation in the same
medium. This method of generating NSPCs has obvious clinical limitations as it requires brain
tissue to generate the renewable cell population.
4.2. Embryonic stem cell (ESC) derived-NSPCs
The first isolation of a pluripotent population of cells from the mouse embryo over 30 years
ago revolutionized the emerging field of regenerative medicine. [79, 80] Once a similar
population of cells were identified and isolated from a human source, [81] the possibilities and
potential for clinical application for the derivatives of these cells became limitless. Neurons
and glial cells were among the first differentiated cells to be generated from these pluripotent
cells. Although there are some differences between human and murine ES cells, such as LIF
responsiveness in vitro [82], many of the neural differentiation protocols established for mouse
ES cells have been adapted for use with human ES cells. There are multiple strategies that are
implemented to generate neural cells from ES cells with varying degrees of cell homogeneity,
differentiation potential, efficiency and time requirements. In general, two strategies exist to
direct ES cells to NSPC: the first uses embryoid body (EB) formation to mimic the physiological
neurodevelopment of the embryo and the second involves removal of all cues that would direct
the cells to a non-ectoderm lineage by limiting cell-cell interactions with low cell density culture
and environmental signals, with serum-free media.
4.2.1. NSPC generation with EB intermediate
Using EB intermediates to generate NSPCs and their differentiated products mimics the
physiological environment that produces neuroectoderm. [83, 84] In brief, the ES cells are
transferred from their expansion conditions on feeder cells to a suspension culture and allowed
to form aggregates. Within a few days, the EBs formed resemble an anterior pre-streak stage
embryo with an epiblast-like core. [85] At this stage the cells are still able to form cells from all
three germ layers. Next conditions are such that they drive the neuroectoderm lineage while
inhibiting the endoderm and mesoderm fates concentrating the NSPC population and thus
yield cells that can differentiate to neurons and glial cells.
The use of retinoic acid (RA) with the EB based neuralization protocols can vastly improve the
neural lineage cells produced. [86, 87] Many studies have shown that RA plays a key role
during neurogenesis, both in vitro conditions as well as physiologically. RA treatment directs
cell towards those of the posterior CNS. [88] The general culturing process involves EB
formation, as described above, for 4 days, followed by RA treatment (4-/4+) and then 1 week
of adherent conditions. A high proportion of the differentiated cells have neural properties,
with positive identification for both glutamatergic and motor neurons. [88, 89]
Other neuralization protocols that use an EB intermediate, such as culturing with carcinoma
or stromal cell-line conditioned media or via selection in defined media conditions, can be used
to generate NSPCs with relatively high efficiency. [90, 91] However, a key limitation with
NSPCs generated from EB intermediates exists; despite success with these approaches,
concerns related to the restricted potential of NSPCs remain. The involvement of EB formation
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creates a risk for the persistence of non-neural cells in the final population. This has been
associated with teratoma formation and increase tumorigenicity. The persistence of non-neural
cell can be traced back to the non-specific differentiation pattern associated with the initial
aggregation of EB.
4.2.2. NSPC generation from default pathway
In order to circumvent EB intermediates, and its limitations, during neuralization of pluripo‐
tent cells, our lab has opted to use the default pathways to direct ES cells to a neural lineage.
([92]; Figure 2) This pathway relies on the fact that, in the absence of extrinsic signaling to form
non-ectoderm lineage, the cells will adopt a neuroectoderm fate. [93, 94] The default mecha‐
nism is based on studies that showed the inhibition of BMP signaling by protein inhibitors or
by gene expression manipulation leads to neural lineage commitment. A small percentage
(0.2%) of single ESCs cultured under serum-free, low cell density condition proliferate in the
presence of LIF to form floating neurospheres of cells that express the neuroepithelial markers
Nestin and Sox1, but downregulate the ES cell markers Oct4 and SSEA1. [93, 94] Moreover, a
small proportion of cells derived from primary neurospheres can generate secondary colonies
when subcloned, which are independent of LIF, but are dependent on FGF2. These cells have
been termed definitive (dNSPC). [94]
In order to assess the clinical potential of the NSPCs generated by this method, with specific
focus on SCI, our lab has extensively characterized the ES-derived dNSPCs in vitro. [92] In brief,
ES cells were directed to primitive and definitive NSPC fates. Their mRNA profile was evaluated
using RT-PCR and in vitro differentiation patterns were quantified and compared to aNSPCs
populations isolated from the SVZ. The ES-dNSPC populations were similar to aNPCs analyzed
at the mRNA level with a significant decrease in pluripotency (Nanog, Oct4) and stemness (Tdgf1,
Dnmt3b, Gaf3) markers with increased transcription of neural-specific markers (Pax6, Nestin,
Olig2, Synaphysin). The pNSPC retained many of the pluripotency and stem markers associat‐
ed with undifferentiated ES cells reflecting the importance of driving the NSPC to a definitive
state. To assess the in vitro differentiation pattern of the ES-derived NSPCs and aNSPC controls,
the cells were cultured on matrigel for one week with 1% FBS media. The cells were immunola‐
belled for NSPCs (Nestin), neurons (BetaIII Tubulin), astrocytes (GFAP), and oligodendro‐
cytes (Olig2, PDGFRa, CNPase). Both ES-dNSPCs and aNSPCs yielded primarily differentiated
neural cells with the majority being astrocytes (~65%). The largest proportion of cells from the
ES-pNSPCs  were  undefined  or  retained  the  NSPC  marker  Nestin.  Although  astrocytic
differentiation may not be the desired cell, this differentiation into astrocytic cells demon‐
strates that the in vitro environment is very different from the in vivo niche.
The potential of these cells to survive, integrate, and differentiate in vivo is critical to evaluating
their role in regenerative medicine applications. Since remyelination following SCI is a likely
potential mechanism of recovery, our lab uses a dysmyelinated Shiverer mouse to assess the
in vivo potential of our ES-dNSPC. Shiverer mice lack compact myelin basic protein (MBP) and
therefore are an ideal candidate to evaluate the myelination ability of these cells. [95] In general,
the Shiverer mouse, under isoflurane anaesthesia, received a T6-T7 laminectomy followed by
4 intraspinal injections of ES-dNSPC (100,000 in 2ul of media). The mice were immune
suppressed with continued cyclosporine A treatment. Six weeks following transplantation the
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animals were perfused and spinal tissue was fixed with 4% PFA. Cryosections of tissue were
immunohistochemically labeled for neural cell markers. The ES-dNSPCs were able to survive
and integrate into the host tissue in a similar pattern to that previously described with aNPCs.
The transplanted cells preferentially migrated to the white matter tracts and differentiated to
oligodendrocytes with multiple processes that expressed MBP. The quantification of the
differentiation pattern showed that the transplanted cells become primary mature APC+
oligodendrocytes with limited astroglial and neuronal fates. The variability between in vivo
and in vitro differentiation potential can be attributed to the instructive nature of the spinal
cord niche. The Shiverer spinal cord has been shown to have greater amounts of NG2-express‐
ing oligodendrocyte progenitors. [96] The environment that leads to the excess of these
progenitors is also acting on the transplanted cells. This instructive/permissive niche could be
a result of signaling molecules such as GRO-1 [97] and neuregulin (NGR) [98], both of which
are released by astrocytes and neurons.
ES cells are the most defined source of readily available pluripotent cells that can be used in
cell-based treatment for SCI. Although, they have some safety and ethical concerns, this
population will remain extremely relevant in the future of spinal cord regeneration.
Figure 2. Default neural differentiation of embryonic stem cells. (A) Schematic representation of neural induction of
ESCs through the default pathway: Individual ESCs when cultured at low density in minimal serum-free media con‐
taining LIF acquire a neural identity through a default mechanism. These neural stem cells colonies are termed
pNSPCs, are LIF- dependent, and divide to form clonally-produced floating neurosphere colonies. pNSPC-derived neu‐
rospheres can be dissociated into single cells and passaged indefinitely in serum-free media containing LIF or can be
passaged into serum-free media containing FGF2 to produce a distinct population of FGF2-dependent cells termed
dNSPCs that also divide to form clonally-produced neurospheres. These spheres can also be passaged indefinitely and
when differentiated produce all three cell types of the neural lineage. (B) Phase-contrast image of a neurosphere colo‐
ny generated by a pNSPC. (C) Phase-contrast image of a neurosphere colony generated by a dNSPC. (D) Phase-con‐
trast image of a neurosphere generated by adult neural stem cells derived from the subependymal layer of the adult
mouse forebrain. For B–D, bar equals 50 mm. ESCs, embryonic stem cells; LIF, leukemia inhibitory factor; dNSPC, defi‐
nitve neural stem cell; pNSPC, primitive neural stem cell; FGF2, basic fibroblast growth factor; Olig2, oligodendrocyte
transcription factor 2. *from Rowland et al., 2011, Stem cell and Develop. 20(11); 1829-1845, with permission.
Regenerative Medicine
http://dx.doi.org/10.5772/55054
281
4.3. Induced pluripotent stem cells (IPSC) derived NSPCs
Given the aforementioned concerns with ES cells combined with the immunogenicity that arises
from allograft transplantation, the search for a patient-specific and accessible cell source has
been  a  principle  endeavor  of  regenerative  medicine.  Historically,  many  techniques  and
strategies have been developed to accomplish this aim, most notably somatic cell nuclear
transfers (SCNT). SCNT is the process by which the nucleus of the somatic cell being reprogram‐
med is transferred to an enucleated ooctye [99]. This technique became famous in the late 1990s
when Dr. Ian Wilmut cloned the first mammal, a sheep named “Dolly”. [100] Although there
is no obvious mechanism that would preclude SCNT from reprogramming human cells, this
technique has yet to be successfully applied in human cells. Furthermore, the requirement for
donor ooctyes, combined with an inefficient and technically difficult processes makes SCNT
unlikely to be a viable option for clinical application even in the most ideal circumstances.
The discovery of IPS cell technology has made a significant stride towards realizing the promise
of patient-specific regenerative medicine. IPS cells are somatic cells that have been reprogram‐
med to ectopically express certain transcription factors that induce an ES cell-like state, in terms
of their differentiation potential and response to in vitro culture conditions. [28] This technolo‐
gy allows for a constant and relatively easy method of generating cells for autologous transplan‐
tation from readily available cell sources such as skin cells. In 2006, Takahashi and Yamanaka
used retrovirus transfected with 24 transcription factors in mouse embryonic fibroblasts (MEF).
[101] Through careful elimination they were able to reduce the required genes to four: OCT4,
Sox2, KLF4 and c-myc. The expression of these four genes was sufficient to revert the MEFs to
an undifferentiated, pluripotent state that was verified using teratoma formation and contribu‐
tion to a chimeric mouse. Since the initial characterization of the iPS cells there has been a
tremendous amount of research further expand and refine the technology. The Yamanaka
factors have been used to reprogrammed various cells from tissues from a variety of species
including mice [101], rats [102], rhesus monkeys [103], and humans [104-107].
The first generation of iPS cell technology is not without its shortcomings and clinical obstacles.
The process of reprogramming can be slow and inefficient and includes oncogenic potential
of the factors themselves, insertion mutatgenesis, and the risks associated with the use of viral
vectors. All of this can contribute to limited clinical translational potential. Fortunately,
substantial research has rapidly developed iPS techniques that are viral vector and mutation
free. For example, piggyBac transposition is a viral-free system that can be used to deliver the
reprogramming factors in both human and mice fibroblasts [108, 109]. A single transposon
containing all four iPS transcription factors is introduced to the cells and reprogrammed
colonies are selected. IPS cell lines with a single insertion site are identified and transposon is
seamlessly excised yielding stable, reprogrammed cell lines that are do not contain any
exogenous DNA or have any insertion mutation. Other viral-free and mutation-free methods
exist including using lentiviruses [110, 111],an episomal system [112], and the use of recombi‐
nant proteins [113], to generate more clinically relevant iPS cells.
Even with the advancement in iPS cell generation, intrinsic differences between ES and iPS
cells exist. IPS and ES are often described as “indistinguishable”, however, key differences
have been identified. The initial characterization of the iPS cells from Takahashi and Yamanaka
noted variation in global gene expression as well as differences in epigenetic characters,
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specifically histone methylation.[101] Epigenetic memory of iPS cells can influence the
differentiation potential and the differentiation of the iPS cells, favouring the identity of the
tissue of origin. [114] The impact of epigenetic variability still remains an area of debate and
methods to optimize iPS cells are underway.
4.3.1. Neuralization of IPS cells
The conceptual outline of how iPS cells may be used in the treatment of SCI is described in
figure 3. [28] Many of the in vitro neuralization protocols outlined above for generating NSPCs
and terminally differentiated neural cells, neurons, astroglia and oligodendrocyte, from ES
cells can be applied to iPS cells. iPS cell have been used in models of Parkinson’s [110, 115],
spinal muscular atrophy (SMA) [116], amyotrophic lateral sclerosis (ALS) [117], and SCI [118].
Although there have been positive results using iPS-derived neural cells for cell-based
treatment, the variation in iPS cells has resulted in variability in the safety and neuralization
of these cells. A comprehensive evaluation of NSPCs from mouse iPS cell lines generated from
various tissue sources and reprogramming methods has shown differences in tumorigenesis
between iPS cell lines compared to NSPCs from ES cell lines. [119]
4.3.2. Improving the IPS neuralization using NOTCH pathway agonism
The variation in neuralization potential between iPS cell lines and their ES cell counterparts
represents an area of regenerative medicine that, if not addressed, could be an obstacle to clinical
translation. Our lab specifically examined the difference in neuralization potential of multi‐
ple iPS cells lines. [120] We used iPS cells generated using piggyBac transposon technology to
eliminate variation that could be attributed to the resurgence of the silenced transgenes or due
to insertion mutations. [108, 109] Furthermore, the default pathway of neuralization was utilized
to avoid issues associated with the EB formation as an intermediate step in generating NSPCs
from a pluripotent cell source. Even with the additional precautions to help generate safe and
clinically-relevant cells, there was retention of plurioptency markers as well as persistence of
non-ectoderm lineage markers. In order for the potential for iPS technology to be realized,
methods to effectively and consistently generate definitive cells must be developed.
We examined the role of BMP antagonism during the initial neuralization of the pluripotent
IPS cells. We identited this as a possible area where IPS cell neuralization could be improved.
Noggin, a BMP antagonist, has previously been shown to increase the number of neurospheres
generated using the default pathway and ESCs.[94] BMPs are involved in directing pluripotent
cells to an endoderm lineage fate. Although the inclusion of Noggin during the in vitro culture
of primary primitive NSPCs did increase the number of neurospheres, it did not affect the
character of the NSPCs as determined by a battery of gene markers analyzed by RT-PCR.
Furthermore, there was no difference on the subsequent mRNA profile between definitive
NSPCs with or without Noggin treatment. These data led us to conclusion that the variability
in the PB-IPS cells’ response to the default pathway is not a result of poor initial neuralization
but likely due to incomplete transition from primitive NSPC to definitive NSPCs state.
The NOTCH pathway has been shown to be involved in many aspects of neurodevelopment
and its role persists in the adult CNS. [121, 122] Disruption in NOTCH signaling leads to a
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reduction in NSPCs while conversely the induction of this pathway promotes NSPCs in vivo.
[123, 124] The NSPC niche of the SVZ expresses receptors and ligands of the NOTCH pathway.
[125] Delta-like ligands (DLL) or Jagged are the principle ligands of the NOTCH pathway, and
interact with the membrane-bound NOTCH receptor. The NOTCH intracellular domain
(NICD) is cleaved by gamme-sectrase. NICD is translocated to the nucleus to facilitate the
transcription of targets such as Hair and enhancer of split, HES genes. [126] Furthermore,
NOTCH appears to play a critical role in transition from primitive to definitive neural state.
Primitive NSPCs were readily generated in LIF-dependent culture conditions from ES cells as
well as NSPCs isolated from E7.5 embyros from NOTCH-deficient sources. However, passage
of these cells to a definitive state was disrupted indicating a crucial role for NOTCH. [124,
127] Using these data we hypothesized that agonizing the NOTCH pathway during the
neuralization of PB-iPSs would improve the neural character of the definitive NSPCs generated
and thus, improve the clinical relevance and translation potential of the cells.
We demonstrated that the addition of recombinant mouse DLL4 to the definitive culture
conditions of the default pathway of neuralization improved the generation of definitive
NSPCs compare to those cells grown in parallel using standard default conditions. [120] DLL4
was selected to this pathway since DLL4 is most avid ligand for the NOTCH1 receptor.[128]
The definitive neurospheres treated with DLL4 produced a greater number of spheres that
retained a free-floating phenotype while untreated spheres showed extensive adhesion and
signs of differentiation. Also, the mRNA profile of the DLL4 treated dNSPC showed a
reduction in pluripotency markers (Lin28, Nanog, Oct3/4) as well as reduction or elimination
of endodermal markers (Gata6, Afp) compared to control cells. This pattern was confirmed at
the protein level with immuncytochemistry. The dNSPCs were also cultured in chamberslides
matrigel in SFM containing 1% FBS to induce the differentiation of the cells. The differentiation
profile of the DLL4-treated definitive NSPCs reflected the ES-derived dNSPCs as well as
aNSPCs. Primarily differentiated neural cells were identified following 1 week of differentia‐
tion with mostly GFAP+ astrocytes in the iPS-dNSPC(+DLL4) group compared to non-treated
iPS-dNSPCs that were primarily positive for the undifferentiated NSPC marker Nestin or were
not labeled by any of the neural markers used. Lastly, the neurons, oligodendrocytes and
astrocytes from DLL4-treated dNSPCs were shown to be electrophysiologically functional.
In addition to the NOTCH pathway, Sonic Hedgehog (SHH) and WNT signaling are both known
to play roles in neurodevelopment. These pathways have been shown to have independent and
interconnected mechanisms of action and there is evidence of considerable crosstalk with
NOTCH signaling. SHH expression can be up-regulated in a time dependent profile with the
Jagged1 in NSPCs in vitro. [125] WNT signaling has been shown to influence the transition of
primitive NSPCs to definitive state through the manipulation of Hes expression. [129, 130]
iPS cell technology combined with the default pathway of neuralization has tremendous
potential to revolutionize the treatment of SCI. Patients could someday use their own skin cells
to regenerate and repair their injury (Figure 3).
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Figure 3. A general schematic representation of the generation of iPS cells, the promotion of neural precursor cells,
and their use in spinal cord remyelination. A: Following a spinal cord injury, demyelination occurs resulting in vulnera‐
ble axons and impaired CNS function. B: The patient’s fibroblasts, or skin cells, are harvested. C: Reprogramming con‐
ditions/factors are introduced to induce self-renewal and pluripotency properties. D: The cells are now iPS cells. E:
When full and independent reprogramming is achieved, reprogramming condition/factors are removed. F: Neuraliza‐
tion of the iPS cell to NPCs under minimal conditions. G: Growth factors (i.e., FGF) further differentiate the cells to be‐
come definitive neurospheres. H: iPS cell-derived neural stem/precursor cells can be injected into the injured spinal
cord. I: Once transplanted, these cells can differentiate CNS cells such as myelinating oligodendrocytes. J: iPS-NPC-
mediated remyelination, or by some unidentified neuroprotective effect, can result in functional recovery following
spinal cord injury. * from Salewski et al., 2010, J. Cell Physiol. 222; 515-521, with permission
5. Transplantation of neural stem/progenitor cells into the injured spinal
cord
5.1. Model of SCI and NSPC transplantation
The in vivo  regenerative and neuroprotective effect  of  the cell-based treatments must be
evaluated in preclinical animal models. The rodent clip compression model of SCI developed
in our lab mimics injuries observed in human SCI, in terms of primary and secondary injury
processes and, in particular, with regards to lesion and cavity formation. This creates a situation
where we can optimize the cell  culture  and transplantation paradigm while  extensively
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characterizing and evaluating the safety and efficiency of our NSPCs in a clinically relevant
small animal model prior to their implementation into larger animal models or a clinical trial.
In general, our SCI model involves injured rats that receive a clip compression injury of spinal
cord either at the cervical or thoracic level. [19, 65] The model characteristics, histopathology,
assessment of axonal integrity, molecular examination of axonal structure, and behavioural
assessment have been extensively characterized. [131-134] This model of moderately severe
SCI, results in a central cavitation and loss of 80% of axons in the spinal cord white matter,
demyelination of the surviving axons in the residual subpial rim and spastic paraparesis.
Following acute (2 week) or chronic (6 weeks) SCI, we have administered four intraspinal
injections of aNSPCs in growth media to the rats at locations 2mm caudal and 2mm rostral to
the injury site. To enhance the survival of the transplanted cells, growth factors [PDGF-AA
bFGF and EGF] in a solution containing aCSF, BSA (100 µg/ml) and gentamycine (50 µg/ml)
has been infused intrathecally to the area of transplantation for 7 days using a microcatheter
connected to an osmotic minipump. A battery of behavioural tests, histological outcomes and
electrophysiological measures are used to determine the therapeutic effect aNPC transplan‐
tation.
5.2. Effect of transplant on subacute and chronic injury
In our study of subacute intervention following SCI, transplantation was delayed to two weeks
following injury. [19] The animals were examined using a number of measures of locomotor
function, including the BBB scale, ladder walk analysis and gait/coordination assessment, for
eight weeks post-SCI. At the eight week endpoint of the experiment, the animals were
euthanized and their tissue collected for histological and electron microscopy.
The transplanted NSPCs had substantial survival (~40%) in the spinal cord when the growth
factor mini osmotic pump was used and these cells demonstrated multipotency. In contrast to
their in vitro differentiation profile, the transplanted cells mostly became oligodendrocytes in
the injured spinal cord. In fact, the cells preferentially migrated to the white matter tract and
showed extensive myelination. ([19]; Figure 4) The role of myelination will be fully addressed
when we discuss potential mechanisms of neuroprotection/neurorepair. Behavioral and
functional benefits from aNSPC engraftment were observed. There was significant locomotor
recovery compared to the injured control groups. The BBB is a 21 point scale that is used to
evaluate hindlimb locomotion in an open field. [43] Immediately following the SCI, all rats
were fully paraplegic and exhibited no hindlimb function. The control rats were able to recover
to a BBB score of 8, denoting plantar placement of the paw without weight support. The
experimental group that received the aNSPC treatment was able to reach a score of 10 on the
BBB. Although a 2-point increase may seem negligible, the BBB is a non-linear scale and these
animals show occasional weight supported plantar stepping which is a substantial functional
improvement. Furthermore, the animals that received the transplanted cells show improve‐
ment on other independent behavioral tests including grid walk and footprint tests. Our results
show that the improved recovery of locomotor function in the transplanted groups was a result
of the effects of the aNPCs since there was no significant difference in the walking ability of
the plain injured or sham controls in all behavioral tests used.
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Figure 4. YFP-NPCs in the spinal cord of a subacutely injured rat 8 weeks after transplantation. A, A confocal image
from a longitudinal section of an injured spinal cord taken from the dorsal spinal cord of a transplanted rat above the
central cavity. A low-magnified image shows the extent of YFP-NPC survival within the injured spinal cord 8 weeks
after transplantation. Grafted YFP-NPCs (green) were dispersed along the rostrocaudal axis of the spinal cord 5 mm
away from the implantation sites (*). YFP-NPCs also migrated to the contralateral site of the spinal cord to a lesser
extent. Double labeling with the neuronal marker betaIII tubulin (Tuj1) showed that YFP-NPCs reside predominantly in
the white-matter area (A–D). Our histological data showed no signs of tumor formation in the spinal cord. E, Confocal
image of a transverse section of the spinal cord from a transplanted rat (8 weeks after transplantation) showing the
distribution of YFP-NPCs in the lateral columns. F, G, YFP cells mainly showed multipolar morphology and extended
numerous branches in the white-matter tissue along the length of axons. WM, White matter; GM, gray matter. * from
Karimi-Abdolrezaee et al, 2006, J Neurosci 26:3377-3389, with permission
The successful implementation of the NSPC therapy in the subacute model is a key step
forward in spinal cord regenerative medicine. It has a relevant therapeutic window, although
narrow, and requires intervention shortly after the initial injury. The chronic injured popula‐
tion represents a large section of the SCI community and currently many of the proposed
treatments cannot be used to repair their injuries. The chronic injured environment is charac‐
terized by many additional challenges including cell loss, a cystic cavity and the inhibitory
influences of the glial scar. [65]
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We noted that when aNSPCs were transplanted at 6 weeks post-SCI, the chronically injured
spinal cord was not an hospitable environment. To address this, we examined methods to
modify the SCI environment to create a permissive environment. Our data suggested that
expression of chondroitin sulfate proteoglycans (CSPG) reduces the survival and thus, the
therapeutic potential of our aNPC treatment. [65] Chondroitinase ABC (ChABC) was admin‐
istered to the chronic SCI environment to breakdown CSPGs that were upregulated as a result
of the injury. We then analyzed the synergistic effect of the transplanted aNSPCs with ChABC
and growth factor pump on the repair and plasticity of the chronically injured spinal cord.
Survival, integration and migration of the transplanted cells in the chronic SCI with ChABC
was extensive compare to treatment without ChABC and growth factors where survival was
low and the transplanted cells remained at the injection site. ([65]; Figure 5) The differentiation
potential of the aNSPCs was similar to that observed in the subacute injury/transplanted
paradigm with the majority of cells displaying oligodendrocyte markers. There was also
improvement observed at the functional locomotor level. The animals that received the
combinatorial treatment of ChABC followed by aNSPCs and GF pump had a significant
improvement on the BBB scale as well as with ladder-walk analysis. These behavioral im‐
provements were also linked to neuroanatomical changes associated with the aNPC therapy.
This is the first successful application of an aNSPC-based treatment for chronic SCI and
represents a critical step forward improving the lives of patient currently living with SCI.
Figure 5. ChABC treatment greatly optimizes NPC transplantation in the chronically injured spinal cord. A–D, Confocal
images of longitudinal and cross sections of chronically injured spinal cord transplanted with NPCs at 9 weeks after
transplantation show a significant increase in the number of surviving NPCs (green) in ChABC-treated spinal cord (C,D)
compared to the vehicle-treated spinal cords (A, B). D, The majority of NPCs integrated within white matter areas in‐
cluding dorsal, lateral, and ventral columns. Quantification of transplant volume revealed a 6.2-fold increase in
ChABC-treated rats (n6, 3.70.79mm3) compared to vehicle-treated rats (n6, 0.60.24mm3) (p0.01, Student’s t test).
NPC cell survival analysis also showed a 5.7-fold increase in number of surviving NPCs (YFP/DAPI-positive cells) in
ChABC-treated rats (28.256.77%) relative to the vehicle-treated ones (4.91.96%) (p0.01, Student’s t test). ChABC treat‐
ment resulted in a significant increase in rostral and caudal migration of NPCs from the injection sites (4.20.50mm)
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compared to vehicle treatment (1.40.4mm)(p0.001, Student’s t test). We also found a 4.6-fold increase in the total
length of rostrocaudal distribution of NPCs in ChABC-treated rats (13.02mmin the best case, average 8.321.5 mm)
compared to vehicle-treated rats (2.24mminthe best case, average 1.820.5mm)(p0.005, Student’s t test). * from Kari‐
mi-Abdolrezaee et al, 2010, J Neurosci 30:1657-1676., with permission
5.3. Possible mechanism of neurorepair/neuroprotection
Although our lab and others have clearly shown that cell-based therapies for SCI can be
beneficial, the mechanisms by which the benefits are achieved still remains an area of debate.
Trophic factor support [40, 135-137] and remyelination [19, 27, 65] as well as other mechanisms
including plasticity and axon integrity have been suggested as possible mechanisms of
recovery with cell-based treatments for SCI.
5.3.1. Trophic factor support
Trophin delivery as a potential mechanism of benefit in cell-based treatments, such as the use
of bone marrow stromal cells (BMSC) following trauma, was first proposed in response to
evidence that there was a degree of neuroprotection despite a lack of survival of transplanted
cells. [40, 135-137] Trophic factors have been shown to have apoptotic effects[138], enhance
axonal regrowth[139], promote endogenous remyelination[140, 141], and neuronal plastici‐
ty[142, 143]. BMSCs as well as aNSPCs have been shown by our lab and others to produces
these trophic factors in vitro, however little evidence to show their involvement in vivo has been
shown. [144]
To study trophin production and involvement in vivo, we examine both brain- and spinal-
derived NPCs, compared them to BMSCs, and transplanted them into injured rat spinal cords.
[145] Candidate trophic factor (NGF, BDNF, NT-3, NT-4/5, GDNF, CNTF, PDGF-A, EGF,
bFGF, LIF, IGF-1, GGF2, TGF-b1, VEGF-A) expression was examined in spinal tissue homo‐
genates as well as specifically in the transplanted cell population by FAC sorting for the eGFP
labeled cells. The neurotrophin levels were increased following SCI and the transplantation of
aNSPC with GF pump further elevated specific trophic factors, in particular, GDNF, LIF and
bFGF. Furthermore, the analysis of the FAC sorted transplanted population of aNSPC showed
increased neurotrophin production, specifically CNTF, EGF and bFGF. The study was the first
to shown that both changes in the host tissue as well as the transplanted aNSPCs can influence
trophic factor levels in vivo. Although further research is required to determine if trophic factor
support is the sole mechanism that conveys neuro-protection or neuro-repair, our research
does shows that it is a likely contributing factor to the functional improvements observed.
5.3.2. Remyelination
Myelin is a critical component of the CNS and is required for its proper functioning. Myelin
is needed for the precise molecular organization of the axon, particularly with regards to nodal
architecture. The arrangement of Na+ channels, K+ channels and contactin-associated protein
at and around the nodes of Ranvier is closely linked to myelin, and a disruption in myelination
results in loss of nodal organization. Furthermore, following SCI there is extensive loss of white
matter and often otherwise functional axons are bare and rendered useless. In this situation,
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restoring the myelination of these axons can have large effects on the overall outcome and
locomotor function since relatively few spared axons can have a tremendous effect on
improving neural outcomes.
These data suggest that the remyelination could be the mechanism by which aNSPC trans‐
plantation is able to repair the injured spinal cord. Following our subacute intervention as well
as chronic injury with combinatorial therapy, we observed migration of engrafted cells to white
matter tracts, mature oligodendrocytic differentiation and expression of myelin basic protein
(MBP) by these cells associated with axons. ([19]; Figure 6) Furthermore, the exogenous
myelination was confirmed by electron microscopy to form multilayer compact myelin around
axons and to restore the nodal architecture as shown by immune labeling for Kv1.2 and panKa.
Figure 6. Exogenous remyelination following subscute SCI with aNSPC transplantation: YFP-NPC-derived oligo‐
dendrocytes generate MBP and ensheath the injured axons of the spinal cord. A–C, Confocal images of longitudinal
sections of an injured spinal cord 8 weeks after transplantation. The area grafted with YFP-NPCs (green) displays a
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robust expression of MBP (red) in the white matter of an injured spinal cord. Cell bodies of donor cells are surrounded
with MBP. Triple-labeling experiments on longitudinal (D–G) and cross (H–K ) sections of spinal cord white matter
showed that MBP-expressing YFP-NPCs ensheathed the injured axons (identified by NF200; blue). These images (D–G)
clearly show the oligodendrocyte morphology of one grafted YFP cell (arrowheads) that extends its processes and ex‐
presses MBP around an injured axon and the close proximity of these cells with newly myelinated axons. L, M, Images
taken by deconvolution confocal microscopy show a higher-magnification image confirming axonal ensheathment of
MBP-expressing YFP-NPCs around the injured axons. *from Karimi-Abdolrezaee et al, 2006, J Neurosci 26:3377-3389,
with permission
Although exogenous myelination has been proposed as a mechanism for aNSPC-mediated
recovery, potential endogenous myelination cannot be ruled out. There is still extensive
research required to delineate the precise role of remyelination and specifically the role of
remyelination induced by transplanted cells.
5.3.3. Other mechanisms
In addition to the roles of trophic support and myelination, other mechanisms have been
proposed. It is possible that effects on axon integrity and neuronal plasticity play key roles in
SCI recovery. We noted positive effects in these areas following our combinatorial strategy of
ChABC and aNSPC in the chronically injured spinal cord.[65] Cortiospinal tract (CST) labeling
using PKC-g and anterograde tracing showed evidence of enhanced axonal integrity and
collateral spouting. This phenomena was seen only at the local level with long-distance CST
regeneration beyond the lesion not observed. Promotion of plasticity of serontonergic (5HT)
fibers was observed with ChABC and aNSPC therapy as noted by a significant increase in its
immunointensity rostral to the injury epicenter. The 5HT positive fibers were observed in areas
of aNSPC engraftment. Many mechanisms are likely working in concert to elicit the behavioral
and functional outcomes observed by our lab and others after application of aNSPC therapy.
6. Conclusions
Spinal cord injury pathology creates a situation where cell-based interventions are attractive
as potential treatments to promote repair and regeneration. There are a variety of cell sources
available for this aim, however, in our research experience, NSPCs are the most likely to
provide lasting and appropriate neurological recovery. Both adult brain and spinal tissue are
sources of NSPCs for transplantation along with the pluripotent cells (ESC and iPSC) when
differentiated in vitro to a restricted NSPC identity. Once transplanted into the injured spinal
cord, the spinal niche directs the NSPCs to terminally differentiated neural cell types, both
neuronal and glial. Our work suggests remyelination via oligodendrocytes is the principal
mechanism of recovery although trophic support as well as neuronal lineages that are created
are other possible mechanisms by which NSPC treatment is beneficial in SCI. Our results with
chronic SCI, which is characterized by cavitation and glial scarring, has shown that stem cell
therapy alone may be of limited benefit. Thus, combinatorial stem cell approaches with
bioengineered strategies, such as use of chondroitinase, will be a key area of future research
in the field of neuro-regenerative medicine.
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